| Next 10 |
Ad
FOLD News and Press Amicus Therapeutics Inc.
News | Amicus Therapeutics Inc. (NASDAQ:FOLD)
-
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. Pa...
-
2025-01-13 12:56:03 ET Summary High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost...
-
2025-01-13 05:56:32 ET More on Amicus Therapeutics Amicus Therapeutics: Cheap Heading Into 2025 Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript Amicus: Teva Settlement Clears Revenue Path Forward For Galafold Morgan Stanley upgrades PTC, cut...
-
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year 1 Strong and Growing Demand for Galafold ® and Pombiliti ® + Opfolda ® Total Revenue Growth of ...
-
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 3:00 p.m....
-
2024-12-27 13:33:36 ET Summary Amicus Therapeutics, Inc.'s shares are down 15% recently despite a profitable 3Q24 and raised FY24 outlook, potentially due to market overreaction. The company markets Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. Galafold...
-
2024-12-19 09:39:13 ET Amid the growing innovations, emphasis on enhanced treatment alternatives, and rapid AI adoption, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider adding high-growth biotech stocks MannKind (MNKD), Amicus Therapeutics (...
-
2024-12-13 14:42:43 ET More on Amicus Therapeutics, Immunocore, etc. Immunocore Is Adequately Valued, But Its Prospects Are Uncertain PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript ...
-
2024-11-17 09:18:23 ET More on Ralph Lauren Ralph Lauren Corporation (RL) Q2 2025 Earnings Call Transcript Ralph Lauren: Attractively Priced As Margins Expand Ralph Lauren: Benefiting From An Improving Brand Ralph Lauren rallies as earnings show momentum into...
-
2024-11-06 12:54:08 ET Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Conference Call November 06, 2024 08:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Jeff Castelli -...
Stock Information
Get FOLD Alerts
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
Ad
-
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. Pa...
-
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year 1 Strong and Growing Demand for Galafold ® and Pombiliti ® + Opfolda ® Total Revenue Growth of ...
-
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 3:00 p.m....